"Oral antiviral candidate Paxlovid™ reduces COVID-19 risks by 89 percent

Paxlovid™, Pfizer’s investigational oral antiviral candidate, displayed

an 89 percent reduction in COVID-19 risks in Phase II/III study.

Pfizer has announced its investigational novel COVID-19 oral antiviral

candidate, Paxlovid™, significantly reduced hospitalisation and death,

based on an interim analysis of the Phase II/III EPIC-HR randomised,

double-blind study of non-hospitalised adult patients with COVID-19, who

are at high risk of progressing to severe illness."

https://www.europeanpharmaceuticalre...by-89-percent/

https://www.pfizer.com/news/press-re...ment-candidat

https://www.bmj.com/content/375/bmj.n2713

"The UK government has purchased 250 000 courses of paxlovid, which is a combination of PF-07321332 and ritonavir*

Commenting on the announcement, England’s health and social care

secretary, Sajid Javid, said, “If approved, this could be another

significant weapon in our armoury to fight the virus alongside our

vaccines and other treatments, including molnupiravir, which the UK was

the first country in the world to approve this week.”

* Справка:

PF-07321332 https://clinicaltrials.gov/ct2/show/NCT04756531

Ritonavir was patented in 1989 and came into medical use in 1996. It is on the World Health Organization's List of Essential Medicines.

Ritonavir was one of the first protease inhibitors developed, but is no

longer used as an anti-HIV drug due to its side effects. However, it is

given at very low doses (too low for anti-HIV effects) to ‘boost’ the

level of other protease inhibitors. https://www.aidsmap.com/about-hiv/ar...heet/ritonavir